AdvanDx

The test MRSA and MSSA directly from blood culture samples in about one hour, compared to between 48 and 72 hours with other methods, the company said. 

The acquisition will provide OpGen with FDA-approved and CE-marked tests for use with its MDRO Gene tests and bioinformatics for multidrug-resistant organisms.

NEW YORK (GenomeWeb News) – AdvanDx, a provider of molecular diagnostics for pathogen identification, said today that it has closed a $12 million Series B-1 financing round.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm AdvanDx today announced it submitted a 510(k) application to the US Food and Drug Administration for clearance of its mecA XpressFISH test for the rapid detection of methicillin-resistant Staphylococcus aureus from S.

AdvanDx said this week that Heiner Dreismann has joined the company's board of directors as an independent director.

NEW YORK (GenomeWeb News) – AdvanDx recently announced the appointment of Alpha Laboratories to support the launch of AdvanDx's molecular QuickFISH test.

The test is the first capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from blood cultures containing Gram-negative rods in less than 90 minutes.

The US Food and Drug Administration has granted 510(K) clearance for AdvanDx's 90-minute Yeast Traffic Light PNA FISH protocol for detecting Candida yeast.

In clinical studies, the test demonstrated 97.1 percent positive agreement and 100 percent negative agreement with conventional methods of testing for MRSA, AdvanDx said.

The 510(k) clearance covers an AdvanDx protocol that speeds up identification of two fungal infections to 90 minutes.

Pages

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.